Study of FSHD2 progression over 18 months
Part of Bones, joints & muscles clinical trials.
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test confirming FSHD2 (a specific change in the SMCHD1 gene).
- You need to be between 18 and 75 years old.
- You must have noticeable weakness in your arms or legs.
- Your weakness level must be rated between 2 and 5 on a simple 0-to-5 scale called the Ricci score.
- You cannot have had certain treatments (like steroids, testosterone) or be in another trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows FSHD patients for 10 years to see how the disease progresses. It includes people who were in earlier FSHD studies and some new patients with genetic confirmation of FSHD.
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
This is a study that follows people who have a confirmed FSHD1 genetic change (and some healthy people for comparison). It may help researchers better understand the condition and how it affects people over time.
This study looks at muscle MRI images and walking patterns (3D gait analysis) in people with FSHD. It helps researchers understand how the disease affects movement and muscle over time.
This trial is testing an investigational drug, SRP-1001, to see if it helps people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. The study will check if the drug is safe and if it can slow down the loss of muscle function.
Hear when a new Facioscapulohumeral Muscular Dystrophy Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.